Lactoferricin Peptides Increase Macrophages' Capacity To Kill Mycobacterium avium

Tânia Silva1,2,3,4, Ana C Moreira1,2, Kamran Nazmi5

  • 1i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.

Msphere
|September 7, 2017
PubMed

Insights

New antimicrobial peptides derived from bovine lactoferricin show promise in treating mycobacterial infections. The d-enantiomer peptide (d-LFcin17-30) effectively kills intracellular Mycobacterium avium by enhancing macrophage antimicrobial mechanisms.

Area of Science:

  • Microbiology
  • Immunology
  • Drug Discovery

Background:

  • Mycobacterial infections pose a global health threat, with treatments hampered by toxicity, cost, and increasing antibiotic resistance.
  • Antimicrobial peptides (AMPs) offer a promising avenue for novel therapeutics due to their broad activity and immunomodulatory potential.
  • Previous studies demonstrated the efficacy of lactoferricin (LFcin) peptides against Mycobacterium avium in broth cultures.

Purpose of the Study:

  • To evaluate the efficacy of LFcin17-30 peptides against Mycobacterium avium within macrophages.
  • To investigate the synergistic effects of LFcin17-30 peptides with ethambutol.
  • To elucidate the mechanism of action of the d-enantiomer peptide (d-LFcin17-30) against intracellular mycobacteria.

Main Methods:

  • Testing LFcin17-30 peptides and their variants against M. avium-infected macrophages.
  • Assessing the combined effect of peptides and ethambutol.
  • Analyzing the localization and cellular effects of d-LFcin17-30 within macrophages, including cytokine production and vesicle formation.

Main Results:

  • LFcin17-30 peptides enhanced the antimicrobial activity of ethambutol against intracellular M. avium.
  • The d-enantiomer peptide (d-LFcin17-30) demonstrated potent direct killing of intracellular M. avium.
  • d-LFcin17-30 induced proinflammatory cytokines and promoted phagosomal maturation and autophagosome-like vesicle formation in macrophages.

Conclusions:

  • d-LFcin17-30 primes macrophages for intracellular microbial digestion, leading to M. avium killing.
  • Lactoferricin-derived peptides represent a potential therapeutic strategy for mycobacterial infections.
  • d-LFcin17-30 exhibits significant immunomodulatory effects on macrophages, suggesting broader therapeutic applications.